LIA
IHE icon

Lynx Investment Advisory’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Lynx Investment Advisory’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$725K Buy
7,322
+455
+7% +$41K 0.24% 106
2026
Q1 		$595K Buy
6,867
+1,623
+31% +$142K 0.28% 80
2025
Q4 		$445K Buy
+5,244
New +$419K 0.24% 96
2024
Q3 		– Sell
-171
Closed -$11.3K – 420
2024
Q2 		$11.3K Buy
+171
New +$11.2K 0.01% 391

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return
MCM
Monument Capital Management Alexandria, Virginia $497M AUM 52.58% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
AWM
Accurate Wealth Management Wesley Chapel, Florida $1.05B AUM 30.92% 1-Year Est. Return
FP
FFG Partners Fort Lauderdale, Florida $352M AUM 70.53% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Lynx Investment Advisory's IHE Position: Q2 2026 in Review

Lynx Investment Advisory increased its iShares US Pharmaceuticals ETF (IHE) stake by 6.6% in Q2 2026, buying an estimated $41K and bringing the position to 7,322 shares worth $725K. The position accounts for 0.24% of the portfolio, ranked #106.

Lynx Investment Advisory first reported a position in IHE in Q2 2024 and has held it in 4 quarters since. 125 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

  • Lynx Investment Advisory held 7,322 shares of iShares US Pharmaceuticals ETF worth $725K as of Q2 2026.
  • Lynx Investment Advisory bought 455 iShares US Pharmaceuticals ETF shares in Q2 2026, an estimated $41K.
  • iShares US Pharmaceuticals ETF made up 0.24% of Lynx Investment Advisory's portfolio in Q2 2026, its #106 holding.
  • Lynx Investment Advisory first reported a position in iShares US Pharmaceuticals ETF in Q2 2024 and has held it in 4 quarters since.
  • 125 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Lynx Investment Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.